Literature DB >> 26776472

Recombinant lipidated dengue-3 envelope protein domain III stimulates broad immune responses in mice.

Chen-Yi Chiang1, Shih-Jen Liu2, Chun-Hsiang Hsieh1, Mei-Yu Chen1, Jy-Ping Tsai1, Hsueh-Hung Liu1, I-Hua Chen1, Pele Chong2, Chih-Hsiang Leng3, Hsin-Wei Chen4.   

Abstract

The linkage of an immunogen with a toll-like receptor ligand has great potential to induce highly potent immune responses with the initial features of antigen-presenting cell activation. In the current study, we expressed recombinant dengue-3 envelope protein domain III (D3ED III) in lipidated form using an Escherichia coli-based system. The recombinant lipidated dengue-3 envelope protein domain III (LD3ED III) augments the expression levels of IL-12 family cytokines. LD3ED III-immunized mice enhance wide ranges of T cell responses as indicated by IFN-γ, IL-17, IL-21 production. Additionally, LD3ED III-immunized mice increase the frequencies of anti-D3ED III antibody producing cells. The boosted antibody titers cover various IgG isotypes, including IgG1, IgG2a, IgG2b, and IgG3. Importantly, LD3ED III-immunized mice induce neutralizing antibody capacity associated with a reduction of viremia levels after challenges. In contrast, mice that are immunized with D3ED III formulated with aluminum phosphate (D3ED III/Alum) only enhance Th2 responses and boost IgG1 antibody titers. Neither neutralizing antibody responses nor the inhibition of viremia levels after challenge is observed in mice that are immunized with D3ED III/Alum. These results suggest that LD3ED III can induce broad profiles of cellular and humoral immune responses.
Copyright © 2016 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Dengue virus; Envelope protein domain III; Lipoprotein; Vaccine

Mesh:

Substances:

Year:  2016        PMID: 26776472     DOI: 10.1016/j.vaccine.2016.01.009

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  DENV-3 precursor membrane (prM) glycoprotein enhances E protein immunogenicity and confers protection against DENV-2 infections in a murine model.

Authors:  Roberto S Dias; Michelle D Teixeira; Mariana F Xisto; John W O Prates; Jessica D Da Silva; Iago O Mello; Cynthia C Da Silva; Sérgio O De Paula
Journal:  Hum Vaccin Immunother       Date:  2020-10-29       Impact factor: 3.452

2.  Immunogenicity of a novel tetravalent vaccine formulation with four recombinant lipidated dengue envelope protein domain IIIs in mice.

Authors:  Chen-Yi Chiang; Chien-Hsiung Pan; Mei-Yu Chen; Chun-Hsiang Hsieh; Jy-Ping Tsai; Hsueh-Hung Liu; Shih-Jen Liu; Pele Chong; Chih-Hsiang Leng; Hsin-Wei Chen
Journal:  Sci Rep       Date:  2016-07-29       Impact factor: 4.379

Review 3.  Recent Developments in Recombinant Protein-Based Dengue Vaccines.

Authors:  Nagesh K Tripathi; Ambuj Shrivastava
Journal:  Front Immunol       Date:  2018-08-23       Impact factor: 7.561

4.  Long-Term Protection Elicited by a DNA Vaccine Candidate Expressing the prM-E Antigen of Dengue Virus Serotype 3 in Mice.

Authors:  Kaihao Feng; Xiaoyan Zheng; Ran Wang; Na Gao; Dongying Fan; Ziyang Sheng; Hongning Zhou; Hui Chen; Jing An
Journal:  Front Cell Infect Microbiol       Date:  2020-03-17       Impact factor: 5.293

Review 5.  A Review on Dengue Vaccine Development.

Authors:  Sheng-Qun Deng; Xian Yang; Yong Wei; Jia-Ting Chen; Xiao-Jun Wang; Hong-Juan Peng
Journal:  Vaccines (Basel)       Date:  2020-02-02

6.  Efficient Uptake of Recombinant Lipidated Survivin by Antigen-Presenting Cells Initiates Antigen Cross-Presentation and Antitumor Immunity.

Authors:  Chen-Yi Chiang; Yi-Jyun Chen; Chiao-Chieh Wu; Shih-Jen Liu; Chih-Hsiang Leng; Hsin-Wei Chen
Journal:  Front Immunol       Date:  2018-04-23       Impact factor: 7.561

7.  A Polypeptide of Tumor-Associated Antigen L6 with Intrinsic Adjuvant Activity Enhances Antitumor Immunity.

Authors:  Yuh-Pyng Sher; Kit Man Chai; Wen-Ching Chen; Kuan-Yin Shen; I-Hua Chen; Ming-Hui Lee; Fang-Feng Chiu; Shih-Jen Liu
Journal:  Vaccines (Basel)       Date:  2020-10-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.